PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer

被引：541

作者：

Glaviano, Antonino ^{[1
]}

Foo, Aaron S. C. ^{[2
]}

Lam, Hiu Y. ^{[3
,4
]}

Yap, Kenneth C. H. ^{[3
,4
]}

Jacot, William ^{[5
]}

Jones, Robert H. ^{[6
,7
]}

Eng, Huiyan ^{[2
,3
]}

Nair, Madhumathy G. ^{[8
]}

Makvandi, Pooyan ^{[9
]}

Geoerger, Birgit ^{[10
]}

Kulke, Matthew H. ^{[11
,12
]}

Baird, Richard D. ^{[13
]}

Prabhu, Jyothi S. ^{[8
]}

Carbone, Daniela ^{[1
]}

Pecoraro, Camilla ^{[1
]}

Teh, Daniel B. L. ^{[14
,15
,16
]}

Sethi, Gautam ^{[2
,3
]}

Cavalieri, Vincenzo ^{[1
]}

Lin, Kevin H. ^{[17
]}

Javidi-Sharifi, Nathalie R. ^{[17
]}

Toska, Eneda ^{[18
]}

Davids, Matthew S. ^{[17
]}

Brown, Jennifer R. ^{[17
]}

Diana, Patrizia ^{[1
]}

Stebbing, Justin ^{[19
]}

Fruman, David A. ^{[20
]}

Kumar, Alan P. ^{[2
,3
]}

机构：

[1] Univ Palermo, Dept Biol Chem & Pharmaceut Sci & Technol, I-90123 Palermo, Italy

[2] Natl Univ Singapore, Natl Univ Singapore Hosp, Dept Surg, Singapore, Singapore

[3] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Pharmacol, Singapore 117600, Singapore

[4] Natl Univ Singapore, Yong Loo Lin Sch Med, NUS Ctr Canc Res N2CR, Singapore 119077, Singapore

[5] Univ Montpellier, Inst Canc Montpellier, Dept Med Oncol, Inserm U1194, Montpellier, France

[6] Cardiff Univ, Museum Ave, Cardiff CF10 3AX, Wales

[7] Velindre Canc Ctr, Museum Ave, Cardiff CF10 3AX, Wales

[8] St Johns Res Inst, Div Mol Med, St Johns Med Coll, Bangalore 560034, Karnataka, India

[9] Wenzhou Med Univ, Quzhou Peoples Hosp, Quzhou Affiliated Hosp, Quzhou 324000, Zhejiang, Peoples R China

[10] Univ Paris Saclay, Gustave Roussy Canc Ctr, Dept Pediat & Adolescent Oncol, Inserm U1015, Paris, France

[11] Boston Univ, Sect Hematol & Med Oncol, Boston, MA USA

[12] Boston Med Ctr, Boston, MA USA

[13] Canc Res UK Cambridge Ctr, Hills Rd, Cambridge CB2 0QQ, England

[14] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore, Singapore

[15] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Anat, Singapore, Singapore

[16] Natl Univ Singapore, Neurobiol Programme, Singapore, Singapore

[17] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA

[18] Johns Hopkins Sch Publ Hlth, Dept Biochem & Mol Biol, Baltimore, MD USA

[19] Imperial Coll London, Div Canc, Hammersmith Campus,Cane Rd, London W12 0NN, England

[20] Univ Calif Irvine, Dept Mol Biol & Biochem, 216 Sprague Hall, Irvine, CA USA

来源：

MOLECULAR CANCER | 2023年 / 22卷 / 01期

关键词：

PI3K; AKT; mTORC pathway; Pan PI3K inhibitors; Isoform-specific PI3K inhibitors; Dual PI3K; mTOR inhibitors; AKT inhibitors; Allosteric mTOR inhibitors; ATP-competitive mTOR inhibitors; Bi-steric mTOR inhibitors; PDK1; inhibitors; Cancer; RENAL-CELL CARCINOMA; FOXO TRANSCRIPTION FACTORS; ADVANCED BREAST-CANCER; PHASE-I TRIAL; PHOSPHATIDYLINOSITOL 3-KINASE INHIBITOR; NONFUNCTIONAL NEUROENDOCRINE TUMORS; CHRONIC LYMPHOCYTIC-LEUKEMIA; INTRAVENOUS PI3K INHIBITOR; PROTEIN-COUPLED RECEPTORS; HEPATOCYTE GROWTH-FACTOR;

D O I：

10.1186/s12943-023-01827-6

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The PI3K/AKT/mTOR (PAM) signaling pathway is a highly conserved signal transduction network in eukaryotic cells that promotes cell survival, cell growth, and cell cycle progression. Growth factor signalling to transcription factors in the PAM axis is highly regulated by multiple cross-interactions with several other signaling pathways, and dysregulation of signal transduction can predispose to cancer development. The PAM axis is the most frequently activated signaling pathway in human cancer and is often implicated in resistance to anticancer therapies. Dysfunction of components of this pathway such as hyperactivity of PI3K, loss of function of PTEN, and gain-of-function of AKT, are notorious drivers of treatment resistance and disease progression in cancer. In this review we highlight the major dysregulations in the PAM signaling pathway in cancer, and discuss the results of PI3K, AKT and mTOR inhibitors as monotherapy and in co-administation with other antineoplastic agents in clinical trials as a strategy for overcoming treatment resistance. Finally, the major mechanisms of resistance to PAM signaling targeted therapies, including PAM signaling in immunology and immunotherapies are also discussed.

引用

页数：37

共 50 条

[41] Novel Approaches for Molecular Targeted Therapy of Breast Cancer: Interfering with PI3K/AKT/mTOR Signaling
Grunt, Thomas W.
Mariani, Gabriella L.
CURRENT CANCER DRUG TARGETS, 2013, 13 (02) : 188 - 204
[42] PI3K/Akt/mTOR pathway as a target for cancer therapy
Morgensztern, D
McLeod, HL
ANTI-CANCER DRUGS, 2005, 16 (08) : 797 - 803
[43] The PI3K/AKT/mTOR Signaling Pathway Is Overactivated in Primary Aldosteronism
Su, Hengchuan
Gu, Yanyun
Li, Fengying
Wang, Qidi
Huang, Baoxing
Jin, Xiaolong
Ning, Guang
Sun, Fukang
PLOS ONE, 2013, 8 (04):
[44] Targeting the PI3K/Akt/mTOR Signaling Pathway: Applications of Nanotechnology
Serej, Forough Alemi
Pourhassan-Moghaddam, Mohammad
Kalan, Mohammad Ebrahimi
Mehdipour, Ahmad
Serej, Zeynab Aliyari
Ebrahimi-Kalan, Abbas
CRESCENT JOURNAL OF MEDICAL AND BIOLOGICAL SCIENCES, 2018, 5 (01): : 7 - 13
[45] The PI3K/AKT/mTOR signaling pathway in breast cancer: Review of clinical trials and latest advances
Khorasani, Ayda Baghery Saghchy
Hafezi, Nasim
Sanaei, Mohammad-Javad
Jafari-Raddani, Farideh
Pourbagheri-Sigaroodi, Atieh
Bashash, Davood
CELL BIOCHEMISTRY AND FUNCTION, 2024, 42 (03)
[46] Naringin inhibits colorectal cancer cell growth by repressing the PI3K/AKT/mTOR signaling pathway
Cheng, Hongyun
Jiang, Xue
Zhang, Qian
Ma, Jun
Cheng, Ronghui
Yong, Hongmei
Shi, Huichang
Zhou, Xueyi
Ge, Liyue
Gao, Guangyi
EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2020, 19 (06) : 3798 - 3804
[47] Everolimus inhibits breast cancer cell growth through PI3K/AKT/mTOR signaling pathway
Du, Liyan
Li, Xiaomei
Zhen, Linhong
Chen, Weiling
Mu, Lingguang
Zhang, Yang
Song, Ailin
MOLECULAR MEDICINE REPORTS, 2018, 17 (05) : 7163 - 7169
[48] Targeting PI3K/AKT/mTOR signaling to overcome drug resistance in cancer
Tufail, Muhammad
Wan, Wen-Dong
Jiang, Canhua
Li, Ning
CHEMICO-BIOLOGICAL INTERACTIONS, 2024, 396
[49] PI3K/Akt/mTOR Pathway Inhibitors in Cancer: A Perspective on Clinical Progress
Wu, P.
Hu, Y-Z
CURRENT MEDICINAL CHEMISTRY, 2010, 17 (35) : 4326 - 4341
[50] Inhibitors of the PI3K/Akt/mTOR Pathway in Prostate Cancer Chemoprevention and Intervention
Roudsari, Nazanin Momeni
Lashgari, Naser-Aldin
Momtaz, Saeideh
Abaft, Shaghayegh
Jamali, Fatemeh
Safaiepour, Pardis
Narimisa, Kiyana
Jackson, Gloria
Bishayee, Anusha
Rezaei, Nima
Abdolghaffari, Amir Hossein
Bishayee, Anupam
PHARMACEUTICS, 2021, 13 (08)

← 1 2 3 4 5 →